BRIEF: XtalPi acquires British chiral molecule developer
AI drug discovery company XtalPi Holdings Ltd. (2228.HK) said on Thursday it has acquired Liverpool ChiroChem Technologies Ltd. (LCC), a developer of novel molecules specializing in chiral molecules. It did not disclose a purchase price.
XtalPi said that LCC has developed a platform that “combines AI software with automation technology, and can virtually screen target molecules in a chiral chemical library of billions of molecules, and efficiently complete the synthesis and put it into physical testing with the help of automated equipment.”
“Through the acquisition, the group’s technical strength in the field of chemical space exploration continues to increase, and its ability to serve domestic and international customers will be further improved,” said XtalPi, also known as QuantaPharm.
XtalPi’s shares were up 4.8% at HK$6.11 in Thursday afternoon trading. The stock is up about 16% from its IPO price of HK$5.28 about a year ago.
By Doug Young
To subscribe to Bamboo Works free weekly newsletter, click here
Related Articles
RELATED ARTICLES
-
NEWS WRAP: Surging Xtalpi seizes on tech rally to raise $267 million
2228.HK -
BRIEF: XtalPi shares surge on Microsoft China partnership
2228.HK
- RNA drug developer Ribo Life targets fresh funding channel
- BRIEF: Shein London IPO approved by British financial regulator
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG
-
Joinn Labs undermined by AI as FDA phases out animal drug testing
6127.HK 603127.SHG
